Study Finds Side Effects of GLP-1 Drugs Could Cause Bone Density Loss

A troubling new study has uncovered another potential side effect of Ozempic, Wegovy, Mounjaro, and other popular glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. According to researchers, these in-demand treatments may be linked to a significant reduction in bone mineral density (BMD), potentially putting users at risk of osteoporosis and fractures. As the medical community grapples with this emerging issue, patients and healthcare providers are left wondering about the long-term implications and whether the benefits of these drugs truly outweigh the risks.

The Growing Popularity of GLP-1 Medications

Ozempic (semaglutide) was first introduced in 2017 as a treatment for type 2 diabetes, part of a new class of medications known as GLP-1 RAs. These drugs work by mimicking the effects of a naturally occurring hormone, stimulating insulin release and reducing blood sugar levels. However, the drug’s weight-loss benefits quickly caught the attention of both patients and healthcare providers, leading to its widespread off-label use as a diet drug.

Amid surging demand for Ozempic as a weight-loss aid, pharmaceutical companies responded by introducing higher-dose versions of GLP-1 drugs, such as Wegovy (also containing semaglutide) and Mounjaro (tirzepatide), which were specifically approved for weight loss. These medications have since been aggressively marketed, contributing to their meteoric rise in popularity and their status as blockbuster treatments used by millions of Americans.

Potential Bone Density Loss Side Effects

While the weight-loss and glycemic-control benefits of GLP-1 medications have been well-documented, a recent study published in the JAMA Network Open journal has uncovered a troubling side effect: a significant reduction in bone mineral density (BMD) among users. Because bone density loss is a major concern with weight loss, the study sought to investigate hip, spine, and forearm bone health after diet-induced weight loss among study participants who received exercise alone, a GLP-1 drug, a combination of the two, or a placebo.

The study, led by researchers from the University of Copenhagen in Denmark, examined data from a randomized clinical trial involving 195 participants between the ages of 18 and 65 with obesity and without diabetes. The researchers found that those who took the GLP-1 drug alone experienced a decrease in BMD in both the hips and spine, despite similar weight loss outcomes to the exercise-only group.

These findings highlight the critical importance of combining GLP-1 treatment with regular exercise to help mitigate the potential negative impact on bone health. The researchers emphasize that the loss of bone density observed in their study could lead to an increased risk of osteoporosis and fractures among GLP-1 medication users.

Gastroparesis and Other Side Effects Linked to Ozempic

The bone density issue is just the latest in a growing list of concerns surrounding widely used GLP-1 medications like Ozempic, Wegovy, and Mounjaro. In recent years, lawsuits have been filed against the manufacturers, alleging that they failed to adequately warn users about the potential for severe gastrointestinal side effects, including a form of stomach paralysis known as gastroparesis.

Gastroparesis, which can leave users with long-term, debilitating digestive issues, has been linked to the use of these GLP-1 drugs. Plaintiffs in the lawsuits claim that the manufacturers, such as Novo Nordisk and Eli Lilly, prioritized profits over patient safety by minimizing the risks in their promotional materials and drug labeling.

In addition to gastroparesis, GLP-1 medications have also been associated with an increased risk of gallstones, cholecystitis (inflammation of the gallbladder), and other gastrointestinal problems. These concerning side effects have further fueled the growing legal battles against the pharmaceutical companies responsible for these drugs.

Ozempic Gastroparesis Lawsuits and Bellwether Trials

In response to the growing number of lawsuits filed against the manufacturers of Ozempic, Wegovy, Mounjaro, and other GLP-1 drugs, the U.S. Judicial Panel on Multidistrict Litigation (JPML) has centralized all related claims in the Eastern District of Pennsylvania. This coordinated effort, known as multidistrict litigation (MDL), is designed to streamline the discovery process and facilitate the resolution of these claims.

As part of the MDL, the parties involved are expected to identify a small group of “bellwether” claims that will be prepared for early trial dates. These test trials will help provide insight into how juries may respond to the evidence and testimony that will be presented across the GLP-1 litigation. The outcomes of these bellwether trials could have a significant impact on the potential for GLP-1 drug settlements or other resolutions for the thousands of claims expected to be filed in the coming months and years.

Ozempic Lawsuit Information

Ozempic lawsuits are alleging a link between the popular diabetes medication and severe gastrointestinal problems. Learn more by clicking on the button.
Scroll to Top